Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
<< anterior 41 a 60 de 231 siguiente >>
Presentar resultados
Seleccionar todas
41. Cita con resumen
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896-904. [Ref.ID 91594]
42.Enlace a cita original
Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011;20:903-13. [Ref.ID 91516]
44. Cita con resumen
Lenzer J, Brownlee S. Why the FDA can't protect the public. BMJ 2010;341:966-8. [Ref.ID 89619]
46. Cita con resumen
Anónimo. Crèmes anesthésiques: surdoses mortelles chez des adultes. Prescrire 2010;30:431. [Ref.ID 88569]
47. Cita con resumen
Anónimo. Patients âgés déments et neuroleptiques: excès de mortalité. Prescrire 2010;30:427-9. [Ref.ID 88568]
48.Tiene citas relacionadas Cita con resumen
Martinez C, Assimes TL, Mines D, Dell'Aniello S, Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 2010;340:352. [Ref.ID 87828]
49.Tiene citas relacionadas
Taylor D. Venlafaxine and cardiovascular toxicity. BMJ 2010;340:327. [Ref.ID 87826]
50. Cita con resumen
Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. [Ref.ID 87323]
51.Enlace a cita original
Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, Langman MJS. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol 2009;68:743-51. [Ref.ID 87164]
52.Tiene citas relacionadas
Besag FMC. Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death. Drug Saf 2009;32:1097-100. [Ref.ID 87023]
54.
Garber AM, Hlatky MA. The confirmatory trial in comparative-effectiveness research. N Engl J Med 2009;361:1498-9. [Ref.ID 86864]
55.Enlace a cita originalTiene citas relacionadas Cita con resumen
Vitiello B, Towbin K. Stimulant treatment of ADHD and risk of sudden death in children. Am J Psychiatry 2009;166:955-7. [Ref.ID 86052]
56.Enlace a cita originalTiene citas relacionadas Cita con resumen
Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009;166:992-1001. [Ref.ID 86051]
57.Tiene citas relacionadas
Ray WA, Murray KT, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. The authors reply. N Engl J Med 2009;360:2137-8. [Ref.ID 85840]
58.Tiene citas relacionadas
Price LH. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:2137. [Ref.ID 85839]
59.Tiene citas relacionadas
Baldessarini RJ. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:2136-7. [Ref.ID 85838]
Seleccionar todas
 
<< anterior 41 a 60 de 231 siguiente >>